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Abstract
Background: The 22q11.2 microdeletion syndrome is a common condition that is associated with cardiac as well as 
extra-cardiac manifestations. Its prevalence and manifestations from north India has not been reported. This study was 
designed to determine the prevalence and ability of clinical criteria to predict 22q11.2 microdeletion.
Methods: A total of 146 cases of cardiac malformation requiring tertiary care at a teaching hospital were prospectively 
screened for 22q11.2 microdeletion using fluorescence in situ hybridization test. Detailed clinical information was 
obtained as per guidelines of Tobias, et al (1999).
Results: Nine out of 146 patients (6.16%) was found to have 22q11.2 microdeletion. All the positive patients showed 
the presence of extra-cardiac features of 22q11.2 microdeletion syndrome. None of the cases with isolated cardiac 
defect were positive for microdeletion.
Conclusions: It seems that 22q11.2 microdeletion syndrome is over-suspected in children with isolated congenital 
heart defects. Screening for 22q11.2 microdeletion should be considered in those cardiac malformation cases which 
have extra-cardiac manifestations in the form of facial dysmorphism and hypocalcaemia.
Background
The 22q11.2 microdeletion syndrome is characterized by
hemizygous microdeletion of 22q11.2 region of chromo-
some 22. It occurs at a frequency of 1 in 4,000 to 6,000
live births [1], and is mostly spontaneous [2]. Mutation of
the TBX1 gene, located in 22q11.2 region, has been sug-
gested as a rare cause of the syndrome [3]. The 22q11.2
microdeletion is found in patients with DiGeorge syn-
drome, Velocardiofacial syndrome and Conotruncal
anomaly face syndromes [4]. Typically, the cardiac anom-
alies involve conotruncus, and include lesions such as
tetralogy of Fallot (TOF: pulmonary stenosis, overriding
aorta, ventricular septal defect & right ventricular hyper-
trophy), truncus arteriosus (TA) [4] and double-outlet
right ventricle besides interrupted aortic arch and sub-
aortic ventricular septal defect.
Several studies have tried to ascertain the incidence of
this condition in general population [1,5,6]; and in
patients with heart disease [7-15], psychiatric disease [16-
20], neonatal hypocalcaemia [21] and velopharyngeal
insufficiency [22]. However, there are very few studies
from India. Most Indian studies are case reports [23-25].
There is only one prospective study from western India
[26]. The prevalence and clinical presentation of the dis-
ease from north India has not been adequately described.
This study was aimed to investigate the prevalence of
22q11.2 microdeletion syndrome in cases with congenital
cardiac malformation with or without other congenital
anomalies (extra cardiac).
Methods
From August 2006 to March 2010, 146 cases of structural
heart defects, with or without extra-cardiac anomalies
including dysmorphic features, that required tertiary care
management at the All India Institute of Medical Sci-
ences prospectively enrolled into the study. They were
referred from various States of north India for tertiary
care management. All the patients have undergone car-
diac catheterization or operative procedure as required
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from the outpatients. The study was approved by the
Institutional Human Ethics Committee.
All patients underwent cardiac, as well as clinical
genetics evaluation including echocardiography and CT/
catheter angiography. Clinical genetics evaluation was
carried out as per guidelines of Tobias, et al (1999) [27]
(Table 1). The relevant morphological features were
recorded.
Molecular cytogenetic study was carried out on both
interphase and metaphase cells. EDTA, as well as hepa-
rinized blood sample was collected from the affected
individuals (0.5-1 ml each). Interphase cell suspension
was prepared by standard method [24]. Blood nucleated
cells were washed in phosphate buffer saline, three times
before hypotonic treatment (50 mMol KCL) for 30 min-
utes and fixation in methanol:acetic acid solution (3:1).
Cells were finally re-suspended in 100 ul of fresh fixative.
Approximately 20 ul of cell suspension was used to pre-
pare the slide. Metaphase spreads were prepared from
phytohaemagglutinin stimulated human peripheral blood
lymphocytes using standard cytogenetic technique.
Microdeletion status was determined by FISH using
non-commercial DNA probes. Bacterial artificial chro-
mosome (BAC)/Phage artificial chromosome (PAC)
clones RP5-882J5 (22q11.2), RP11-22M5 (22q11.22) &
CTA-154H4 (22q11.21) spanning approximately 2 mega
base (Mb) in length from 22q11.21 through 22q11.23
(microdeletion detection limit of >90% in patients with
DiGeorge anomaly) were obtained from European
Resource Centre for Molecular Cytogenetics, University
of Bari, Italy http://www.biologia.uniba.it/rmc/; courtesy
Professor Mariano Rocchi) for the study. The clones were
received as bacterial LB agar stab culture, which were
sub-cultured on LB agar plate before growing in large
amount in LB medium. Probe DNA was extracted using a
commercial BAC extraction kit (Sigma, India). All probes
were labelled using nick translation method with FITC-
12-dUTP (Roche) or TRITC-12-dUTP (Roche) or Cy3
(Amersham, UK). Working concentration of probe DNA
was between 100-200 ng/μl.
Slide was washed in acetic acid for 2 min, and dehy-
drated in 70, 90, 100% ethanol, 3 min each. Nuclei on the
slide were digested with pepsin (100 mg/ml) in 0.01 N
HCl for 20 min at 37°C, rinsed in double distilled water
and followed by PBS, and fixed in 1 % paraformaldehyde
in PBS for 10 min at 4°C. Slides were then rinsed in PBS,
twice in double distilled water and then dehydrated
through ethanol series as before. The hybridization buffer
(60% formamide, 2× SSC, 10% dextran sulphate, Sigma,
USA) containing labelled probe was applied to the slides
under a circular cover slip (11 mm in diameter). The
probes and nuclear DNA were denatured together at
76°C for 6-7 min. Hybridization was performed in a dark
moist chamber at 37°C for overnight. After hybridization,
cover slips were removed and slides were washed with
NP40 (0.03% solution) at 72°C for 2-3 min, followed by
NP40 (0.01% solution) for 2 min at room temperature.
Then slides were dehydrated in ethanol series, as before
and mounted in antifade (Vector, USA) with 1 μg/ml 4,6
diaminidino-2- phenylindol (DAPI; Sigma, USA). The
slides were screened under Olympus BX 51 fluorescent
microscope with 100 watt mercury bulb using 100× plan-
apochromatic objective and single band pass filter for
DAPI, FITC and TRITC (Olympus Japan). FISH image
was captured through spectral imaging system. A total of
at least 1000 interphase nuclei and at least 10 metaphase
nuclei were scored from each case. Presence of two sig-
nals in 100% metaphases and 90% interphase cells was
considered as normal whereas demonstration of one sig-
nal in 100% metaphases or 85-90% interphase cells was
considered as microdeletion positive. When presence of
Table 1: shows clinical features that should lead to consideration of FISH analysis for possible 22q11.2 microdeletion 
(adapted from Tobias, et al 1999) 
Column A Column B Column C
Presence of one of the following Presence of two or more of the following core 
features
Presence of one core feature plus one of these 
associated features
Conotruncal cardiac anomaly such as Fallot's 
tetralogy, interrupted aortic arch, truncus 
arteriosus or major aorto-pulmonary collateral 
arteries
Characteristic facial abnormalities viz. broad 
bulbous nose, square shaped tip of nose, short 
philtrum, telecanthus, slanting eyes, low set 
ears, etc
Long slender fingers and hands
Parent of an affected child Non-conotruncal congenital cardiac defect Short stature
Learning difficulties/developmental delay Hypotonia
Cleft palate, velopharyngeal insufficiency or 
swallowing difficulty
Renal abnormalities or Potter sequence
Hypocalcaemia Psychiatric (especially bipolar) disorders
Immunodeficiency or thymic hypoplasia Family history of congenital cardiac defects
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well as in metaphase (10% deleted) cells was observed,
the case was considered to have mosaicism.
Results
A total of 146 consecutive cases with congenital struc-
tural heart defect requiring surgical treatment were stud-
ied by FISH. The mean age of the patients was 7.7 years,
range 5 days to 29 years. There were 97 males and 49
females. Among 146 cases seventy six patients had
conotruncal heart defect and 70 had non-conotruncal
heart defect (Table 2). Typical clinical features of 22q11.2
microdeletion syndrome were seen in 87 cases. Isolated
heart defect was seen in 59 cases. Out of 146 patients,
nine patients had hemizygous 22q11.2 microdeletion
(6.16%); 6 in non-mosaic form and 3 in mosaic form
(Tables 2 and 3; Figure 1 &2). One mosaic patient had
trigonocephaly due to craniosynostosis of the metopic
suture. No patient with isolated cardiac malformation
was found to have a 22q11.2 microdeletion. All patients
with microdeletion were detected by RP5-882J5
(22q11.2) probe. Other two probes i.e., RP11-22M5
(22q11.22) & CTA-154H4 (22q11.21) were negative for
hemizygous microdeletion. All karyotypes were normal
with conventional cytogenetic analysis.
Table 2: shows details of structural cardiac malformation in relation to extra-cardiac malformations
Defects With extra-cardiac 
malformation
Without extra-cardiac malformation 
(isolated heart defect)
Total
Conotruncal Anomalies 57 19 76
TOF 49 18 67
Non TOF 08 01 09
Non-Conotruncal Anomalies 30 40 70
VSD 03 15 18
ASD 00 07 07
Multiple anomalies (2 or more combinations of pulmonary 
stenosis, VSD, ASD, AVSD, coarctation of aorta, PDA, etc)
27 18 45
Total 87 59 146
Conotruncal Anomalies: tetralogy of Fallot, truncus arteriosus communis, double-outlet right ventricle, persistent truncus arteriosus
TOF: Pulmonary stenosis, overriding aorta, ventricular septal defect, right ventricular hypertrophy
Additional findings: stenosis of the left pulmonary artery, bicuspid pulmonary valve, right-sided aortic arch, a foramen ovale, or atrial septal 
defect, an atrioventricular septal defect
Table 3: shows clinical manifestations of patients with 22q11.2 microdeletion (n = 9)




Interphase FISH Result *RP5-882J5 (22q11.2) deleted
1 96 months Female Muslim TOF FD, BD, LD/DD 93% interphase cells with hemizygous microdeletion
2 14 months Male Hindu TOF FD, HT, LD/DD 98.5% interphase cells with hemizygous microdeletion
3 33 months Male Hindu TOF FD, HT, SS, LD/DD Mosaic; 8% normal interphase cells (metaphase: 2 without & 18 
with hemizygous microdeletion)
4 18 months Male Hindu TOF FD, CS, LD/DD Mosaic; 15% interphase cells with hemizygous microdeletion 
(metaphase: 1 with & 9 without hemizygous microdeletion)
5 75 days Male Hindu TOF FD, VPI, DD, HC 96% interphase cells with hemizygous microdeletion
6 55 days Female Hindu TOF FD, HC 97.5% interphase cells with hemizygous microdeletion
7 60 days Male Hindu TOF FD, HC 94% interphase cells with hemizygous microdeletion
8 36 months Female Hindu TOF FD, LD/DD 95% interphase cells with hemizygous microdeletion
9 10 months Male Hindu TOF FD, DD Mosaic; 30% interphase cells with hemizygous microdeletion 
(metaphase: 3 with & 8 without hemizygous microdeletion)
TOF = tetralogy of Fallot; FD = facial dysmorphism; LD/DD = learning difficulties/developmental delay; BD = behavioural disorder; HT = 
hypotonia; SS = short stature; CS = craniostenosis (metopic suture); HC = hypocalcaemia; VPI = velopharyngeal insufficiency
*Other 2 probes i.e., RP11-22M5 (22q11.22) & CTA-154H4 (22q11.21) were found dizygous (i.e., not deleted)
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Figure 1 Non-mosaic 22q11.2 microdeletion case. (A) Front view of face is showing broad nose, square shaped tip of nose, small philtrum, hyper-
telorism, telecanthus, squint and low set ears. (B) FISH image is showing one signal, indicating hemizygous 22q11.2 microdeletion.
A
B
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Figure 2 Mosaic 22q11.2 microdeletion case. (A) Front view of face is showing broad nose, square shaped tip of nose, small philtrum, hypertelor-




Halder et al. BMC Medical Genetics 2010, 11:101
http://www.biomedcentral.com/1471-2350/11/101
Page 6 of 7Discussion
The association of conotruncal cardiac defect with hem-
izygosity for the region of 22q11.2 is taken as an evidence
for genetic basis of congenital heart defects [28,29]. This
syndrome shows wide variability in penetrance and
expressivity, hence cases differs each other. As molecular
probes for this region are now readily available, the diag-
nosis of 22q11.2 microdeletion is routinely performed
[30,31] despite phenotypic variability.
The cases included in the present study are not repre-
sentative of the general population as they were specifi-
cally referred for tertiary care at our hospital; hence,
more likely to be severe cases. In this prospective study,
we have found that 6.16% of the structural congenital
heart defect patients were positive for 22q11.2 microdele-
tion (hemizygosity with RP5-882J5 clone). All microdele-
tion positive cases had characteristic extra-cardiac
manifestations besides cardiac defect as tetralogy of
Fallot (Table 3). This frequency is towards the lower side
of other similar reports (TOF 6% to 21%, PA/VSD 32% to
48%) [32,33]. Although, another report from western
India has also found a frequency of 5.7% (with commer-
cially available probes), but in contrast to this report we
did not find any 22q11.2 microdeletion in isolated ASD
(nil vs 6.6%) or VSD cases (nil vs 12%) [26] (Table 2). A
study by Jiang et al (2005) has found 2 of 4 isolated Tetral-
ogy of Fallot and 1 of 5 isolated VSD patients to be posi-
tive for 22q11.2 microdeletion [34]. Similarly, Gioli-
Pereira et al (2008) have found 22q11.2 microdeletion in 8
of 123 patients (6.5%) with isolated congenital heart
defects [35]. This could be due to non recognition of
other associated cardiac anomalies (may be due to
incomplete investigation) and extra cardiac features (may
be overlooked due to severity of the cardiac disease).
Such discrepancies can be minimized by adhering to
guidelines for clinical diagnosis laid down by Tobias et al.
(1999) [27] (Table 1). Guidelines suggest that FISH analy-
sis should be performed on those patients who meet at
least one of the criteria in column A. Any patient with a
conotruncal cardiac anomaly, even in isolation, deserves
to be investigated for presence of 22q11.2 microdeletion,
because microdeletion is frequently associated (~50%).
Alternatively, history or presence of two features in col-
umn B, or one feature in column B and an additional fea-
ture in column C regarded as sufficient to merit FISH
investigation. These guidelines were proposed with the
aim of achieving high sensitivity for FISH analysis. Our
experience, through this study, does not support FISH
analysis on isolated cardiac malformations. More criteria
need to be incorporated for better pick up of microdele-
tion positive cases. Guidelines for 22q11.2 microdeletion
screening have also been reported by Digilio et al (1999)
[36]. They favor 22q11 microdeletion testing only in
patients with associated classic or subtle clinical anoma-
lies falling within the phenotypic spectrum of 22q11
microdeletion, and in those presenting with distinct ana-
tomic conotruncal defect subtypes. Our study supports
these guidelines.
This syndrome is inherited from parents in 5-10% of
cases with 50% risk for transmission. Hence, it is recom-
mended (also by Tobias et al. 1999) to consider FISH
analysis for possible 22q11.2 microdeletion to parents of
all affected child. It seems also reasonable to offer prena-
tal diagnosis where required.
Conclusion
It is concluded that 22q11.2 microdeletion syndrome is
over-suspected in children with isolated congenital heart
defects. We recommend routine FISH testing in cases
with conotruncal congenital heart disease associated with
extra cardiac anomalies (e.g., dysmorphic features or
hypocalcaemia).
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